Physician profile
Anderson D Eng
NPI 1831528363
$2,305.73
in general payments reported to CMS, 2019-2025
19 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $244 · 2021: $311 · 2022: $352 · 2023: $242 · 2024: $377 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,006.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $427.55 | 2019-2025 | |
| Gilead Sciences, INC. | $348.67 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $251.41 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Astrazeneca Pharmaceuticals LP | $159.91 | 2021-2024 | Breztri, Fasenra, Farxiga |
| Amarin Pharma, INC. | $129.20 | 2019-2021 | |
| Glaxosmithkline, LLC. | $121.31 | 2020-2024 | Shingrix, Arexvy |
| Amgen INC. | $109.79 | 2022-2025 | Evenity, Prolia, Prolia |
| Dynavax Technologies Corporation | $104.67 | 2022-2024 | Heplisav-B |
| Novo Nordisk INC | $95.52 | 2023-2025 | |
| Scilex Pharmaceuticals INC. | $82.55 | 2023-2025 | Ztlido |
| E.R. Squibb & Sons, L.L.C. | $72.49 | 2023-2024 | Eliquis |
| Lilly USA, LLC | $71.67 | 2020-2025 | Zepbound, Mounjaro |
| Insmed, INC. | $70.60 | 2025 | Arikayce |
| Agios Pharmaceuticals, INC. | $66.77 | 2024-2025 | Pyrukynd |
| Radius Health, INC. | $49.21 | 2020-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $44.85 | 2022 | |
| Xeris Pharmaceuticals, INC. | $42.28 | 2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.30 | 2020-2025 | Jardiance |
| Modernatx, INC. | $16.98 | 2025 | Mresvia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anderson Eng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.